

# Prevention & Intervention



– Where Preventive Cardiology  
Meets Interventional Cardiology

---

*3rd Central and Eastern Europe Summit*

---

*2025 Edition*

*Prevention & Intervention Heart Team  
– Complex Patients, Shared Decisions*

*OCTOBER 10–12, 2025 | WARSAW & ONLINE*

# PROGRAMME

[www.prev-interv.com](http://www.prev-interv.com)

# Course Directors



## **Marta Kałużna-Oleksy**

*MD, PhD, MBA, FESC*

1<sup>st</sup> Department of Cardiology

University of Medical Sciences in Poznan, Poland

University Hospital in Poznan, Poland

Chair of EAPCI Gender & Disparities Committee

President of the Polish Association of Acute Cardiovascular Care 2025-2027



## **Izabella Uchmanowicz**

*RN, PhD, MBA, FESC, FHFA*

Dean of the Faculty of Nursing and Midwifery, Wrocław Medical

University, Wrocław, Poland

Past-President ACNAP

Board Member of the Polish Cardiac Society



## **Michał Hawranek**

*MD, PhD, FESC*

Director of Catheterization Laboratory, Silesian Center for Heart Disease

Third Department of Cardiology, Medical University of Silesia in Katowice

President of the Association for Cardiovascular Interventions of Polish

Cardiac Society 2023-2025

Co-Chair EAPCI National Cardiac Societies Committee



## **Bartosz Hudzik**

*MD, PhD, FESC, FACC*

Head

Department of Cardiovascular Disease Prevention

Faculty of Public Health in Bytom

Medical University of Silesia in Katowice

Senior Cardiologist

Third Department of Cardiology, Silesian Center for Heart Disease

School of Medicine with a Division of Dentistry,

Medical University of Silesia

# Guest Faculty

Aleksander Araszkiwicz  
Maciej Banach  
Shrilla Banerjee  
Emanuele Barbato  
Agata Bielecka-Dąbrowa  
Piotr Buchta  
Piotr Buszman  
Aaysha Cader  
Stephane Carlier  
Fizzah Choudry  
Michał Czapla  
Maciej Dąbrowski  
Kyriakos Dimitriadis  
Anthony Dissen  
Anna Draus  
Dariusz Dudek  
Magdalena Dudek  
Marcin Fijałkowski  
Marek Gierlotka  
Robert J. Gil  
Marcin Grabowski  
Marek Grygier  
Mark Hayter  
Zenon Huczek  
Ivan Ilic  
Miłosz Jaguszewski  
Petr Kala  
Nicole Karam  
Cezary Kępka  
Janusz Kochman  
Łukasz Kołtowski  
Mila Kovacevic  
Marek Koziński  
Grzegorz Kubiela  
Wiktor Kuliczkowski  
Marcin Kurzyna  
Ekaterini Lambrinou  
Christopher Lee  
Jacek Legutko

Stephane Manzo-Silberman  
Maciej Marciniak  
Giulia Masiero  
Anna Mikołowicz-Mosiądz  
Carmen Moldovan  
Jakub Morze  
Ulvi Mirzoyev  
Jacek Niedziela  
Tadeusz Osadnik  
Michael Papadakis  
Valeria Paradies  
Biljana Parapid  
Radostaw Parma  
Milovan Petrović  
Massimo Piepoli  
Joanna Popiołek-Kalisz  
Aleksander Prejbisz  
Jerzy Pregoński  
Łukasz Pyka  
Jamal Rana  
Sarita Rao  
Nicola Ryan  
Bartosz Rymuza  
Pierre Sabouret  
Jerzy Sacha  
Francesco Saia  
Antonia Sambola  
Piotr Scisło  
Rokas Serpytis  
Anastasiya Skoromna  
Wojciech Skorupski  
Grzegorz Sobieszek  
Alicja Sołtowska  
Sebastian Szmit  
Radostaw Targoński  
Wojciech Wojakowski  
Michał Wróbel  
Ercole Vellone





# FRAMEWORK PROGRAMME

# 2025.10.10 Friday

ROOM B	ROOM C
<p>12:00-15:00 WORKSHOP/WARSZTAT</p> <p><b>Heart Valves in Focus – Modern Transcatheter Therapies in Everyday Clinical Practice</b> <i>Zastawki pod kontrolą – nowoczesne terapie przezcewnikowe w codziennej praktyce klinicznej</i></p>	<p>12:00-16:30 WORKSHOP/WARSZTAT</p> <p><b>Modern PCI Strategies in Clinical Practice – From Imaging to Optimization of Coronary Procedures: An Interactive Workshop</b> <i>Nowoczesne strategie PCI w praktyce klinicznej – od obrazowania po optymalizację zabiegów wieńcowych – warsztat interaktywny</i></p>
15:00-16:00 Coffee break/Przerwa kawowa	
<p>16:00-18:00 WORKSHOP</p> <p><b>Creating an Inclusive Environment for LGBTQIA+ Patients and Populations: A Culturally Competent Approach to Preventative Care</b></p>	
18:00-18:30 Coffee break/Przerwa kawowa	
<p>18:30-19:30</p> <p><b>Patient at the Centre: A Worldwide Perspective on Patient Empowerment and Partnership in Cardiovascular Care</b> <i>Pacjent w centrum: globalna perspektywa wzmocnienia roli pacjenta i partnerstwa w opiece kardiologicznej</i></p>	



# 2025.10.11 Saturday

ROOM A	ROOM B
9:00-10:10 Session 1.  <b>Building the Prevention &amp; Intervention Heart Team</b>	
10:10-10:25 Coffee break/Przerwa kawowa	
10:25-11:35 Session 2.  <b>From vulnerable plaque to vulnerable patient: Redefining cardiovascular risk</b>	
11:35-11:50 Coffee break/Przerwa kawowa	
11:50-13:00 Session 3.  <b>Core risk drivers in ASCVD: Lipids, inflammation, glucose, and pressure</b>	12:30-14:00 WORKSHOP  <b>Maximising Success in Publishing Research Papers</b>
13:05-13:50 Lunch	
13:50-15:00 Session 4.  <b>Systemic disease and comorbidity: Accelerators of cardiovascular instability</b>	
15:00-15:15 Coffee break/Przerwa kawowa	
15:15-16:25 Session 5.  <b>Precision prevention and future therapies in ASCVD</b>	
16:25-16:40 Coffee break/Przerwa kawowa	
16:40-17:50 Session 6.  <b>Advanced coronary disease: Managing complex atherosclerosis</b>	
17:50-18:05 Coffee break/Przerwa kawowa	
18:05-19:15 Session 7.  <b>Bleeding, vulnerability and complexity: How to treat the unstable patient</b>	

# 2025.10.10 Sunday

ROOM A	ROOM B	FOYER
9:00-10:10 Session 8.  Destabilized: Hemodynamic collapse and the role of circulatory support		
10:10-10:25 Coffee break/Przerwa kawowa		10:00-12:00 Abstract Session
10:25-10:55 Session 9.  ESC guidelines in practice: Heart Team in action – Real cases with guidelines approach Part 1. Multivessel disease in a diabetic patient: Strategy beyond revascularization – what do the ESC guidelines say?	10:25 - 11:55  Case challenge with Shockwave IVL	
10:55-11:25 Session 9.  ESC guidelines in practice: Heart Team in action – Real cases with guidelines approach Part 2. Bleeding risk vs ischemic benefit: PCI in an octogenarian with AF and CKD – what do the ESC guidelines say?		
11:25-11:55 Session 9.  ESC guidelines in practice: Heart Team in action – Real cases with guidelines approach Part 3. Young patient with multimorbidity – multilevel atherosclerosis, arrhythmia, and valvular heart disease – what do the ESC guidelines say?		
11:55-12:10 Coffee break/Przerwa kawowa		



# 2025.10.10 Sunday

12:10-13:20 Session 10.  <b>Decoding HFpEF: From diagnosis to multidisciplinary care and the patient voice</b>		
13:20-13:35 Coffee break/Przerwa kawowa		
13:35-14:45 Session 11.  <b>Obesity in women</b>		
14:45-15:00 Coffee break/Przerwa kawowa		
15:00-16:10 Session 12.  <b>The Prevention&amp;Intervention Heart Team model: Putting it all together</b>		
13:00-15:00 Lunch		

# PROGRAMME



# 2025.10.11 Saturday ROOM A

- 9:00 – 10:10 **Session 1.**  
**Building the Prevention & Intervention Heart Team**  
CHAIR  
*Izabella Uchmanowicz, Shrilla Banerjee*  
PANEL  
*Christopher Lee, Antonia Sambola, Sarita Rao, Petr Kala*
- 9:00 – 9:12 The global burden of ASCVD: Where are we and what needs to change?  
→ overview of the current cardiovascular disease burden and identification of key unmet needs.  
*Michael Papadakis*
- 9:12 – 9:24 Modifiable risk factors in ASCVD: From knowledge to population impact  
→ the significance of classical and novel risk factors, and effective strategies for risk reduction.  
*Maciej Banach*
- 9:24 – 9:36 Non-invasive diagnostics in ASCVD: Tools for early detection and future innovation  
→ imaging and biomarkers for early identification of high-risk patients.  
*Marta Kałużna-Oleksy*
- 9:36 – 9:48 Invasive diagnostics and treatment strategies: Evolving concepts in risk-guided intervention  
→ role of FFR, iFR, OCT, IVUS, microvascular assessment, and inflammatory diagnostics — today and tomorrow.  
*Kyriakos Dimitriadis*
- 9:48 – 10:00 Integrating prevention and intervention: Heart Team models, benefits, and challenges  
→ how to build an interdisciplinary team linking prevention and intervention — what works and what needs to evolve.  
*Michał Hawranek*
- 10:00 – 10:10 Discussion
- 10:10 – 10:25 Coffee break

# 2025.10.11 Saturday ROOM A

10:25 – 11:35 **Session 2.**

## **From vulnerable plaque to vulnerable patient: Redefining cardiovascular risk**

**CHAIR**

*Michał Hawranek, Marta Kałużna-Oleksy*

**PANEL**

*Agata Bielecka-Dąbrowa, Biljana Parapid, Antonia Sambola*

**10:26 – 10:38** Defining the vulnerable patient: Systemic risk beyond the lesion  
→ who is truly at risk of sudden cardiovascular events? From traditional risk factors to dynamic systemic models.

*Aleksander Prejbisz*

**10:38 – 10:50** Vulnerable plaques: What makes a lesion dangerous?  
→ anatomical, biological, and functional features of rupture-prone plaques — identification and clinical significance.

*Petr Kala*

**10:50 – 11:02** Non-invasive imaging in risk stratification: Can we see the unstable plaque?

→ the role of CTA, CMR, PET and other imaging techniques in detecting unstable plaques and high-risk patients.

*Cezary Kępka*

(Sponsored Lecture by Siemens Healthineers)

**11:02 – 11:14** Pharmacological stabilization of the vulnerable patient: What works today?

→ plaque-stabilizing drugs: Statins, pcsk9 inhibitors, lp(a)-lowering agents, anti-inflammatory and antiplatelet therapies.

*Milovan Petrović*

**11:14 – 11:26** Can intervention become prevention? Early action to prevent events

→ should we treat non-critical but high-risk lesions? Evidence, controversies, and future directions.

*Francesco Saia*

**11:26 – 11:35** Discussion

**11:35 – 11:50** Coffee break



# 2025.10.11 Saturday ROOM A

- 11:50 – 13:05 **Session 3.**  
**Core risk drivers in ASCVD: Lipids, inflammation, glucose, and pressure**  
CHAIR  
*Francesco Saia, Mitoz Jaguszewski*  
PANEL  
*Pierre Sabouret, Ercole Vellone, Stephane Carlier, Aleksander Prejbisz*
- 11:51 – 12:03 Dyslipidemia and lipoprotein risk: From LDL to Lp(a)  
→ atherogenic lipoproteins as drivers of plaque growth and destabilization.  
*Pierre Sabouret*
- 12:03 – 12:15 Chronic inflammation in ASCVD: A persistent ignition source  
→ low-grade systemic inflammation as a central mechanism of vascular injury.  
*Marek Gierlotka*
- 12:15 – 12:27 Diabetes and insulin resistance: The metabolic substrate of vascular risk  
→ the role of hyperglycemia, oxidative stress, and endothelial dysfunction.  
*Alicja Sottowska*
- 12:27 – 12:39 Hypertension and hemodynamic stress: More than just numbers  
→ pressure variability and shear stress as contributors to plaque rupture risk.  
*Rokas Serpytis*
- 12:39 – 12:51 Interventional Treatment for Hypertension Management: Broad application or patient-specific therapy?  
*Aleksander Prejbisz*
- 12:51 – 13:00 Discussion
- 13:00 – 13:05 PoWIZYCIE – innowacyjna platforma wspierająca prewencję i edukację pacjentów  
*Paulina Wierzbicka*
- 13:05 – 13:50 Lunch

# 2025.10.11 Saturday ROOM A

- 13:50 – 15:00 **Session 4.**  
**Systemic disease and comorbidity: Accelerators of cardiovascular instability**  
CHAIR  
*Sebastian Szmit, Kyriakos Dimitriadis*  
PANEL  
*Carmen Moldovan, Rokas Serpytis, Marek Gierlotka*
- 13:51 – 14:03 Chronic kidney disease and cardiovascular risk: The cardio-renal continuum  
→ uremic toxins, mineral imbalance, and volume overload as atherogenic factors.  
(scientific grant from Boehringer Ingelheim)  
*Marcin Grabowski*
- 14:03 – 14:15 Autoimmune diseases and inflammatory burden: A hidden cardiovascular threat  
→ immune system activation and its impact on endothelium and thrombosis.  
*Jakub Morze*
- 14:15 – 14:27 Psychosocial risk factors: When the mind fuels the heart  
→ sleep disorders, depression, and stress as modulators of vascular inflammation.  
*Izabella Uchmanowicz*
- 14:27 – 14:39 Cancer, therapy-related inflammation and cardiovascular risk  
→ how malignancy and treatments accelerate atherothrombosis.  
*Sebastian Szmit*
- 14:39 – 14:51 What do we know from studies about obesity as a cardiovascular risk factor and how can we modify it effectively  
*Joanna Popiótek-Kalisz*
- 14:51 – 15:00 Discussion
- 15:00 – 15:15 Coffee break



15:15 – 16:25 **Session 5.**

## **Precision prevention and future therapies in ASCVD**

**CHAIR**

*Tadeusz Osadnik, Sarita Rao*

**PANEL**

*Michał Czapla, Anthony Dissen, Ekaterini Lambrinou, Jakub Morze*

- 15:16 – 15:28** Treating obesity as a cardiovascular disease: From weight to risk reduction  
→ addressing obesity as an atherogenic condition.  
*Michał Czapla*
- 15:28 – 15:40** Genetics and polygenic risk in ASCVD: Clinical applications and future potential  
→ from rare variants to polygenic risk scores and targeted therapies.  
*Jamal Rana*
- 15:40 – 15:52** Artificial intelligence and predictive modeling in ASCVD prevention  
→ AI integration for risk stratification and personalized therapy.  
*Jacek Niedziela*
- 15:52 – 16:04** Health empowerment and AI for rehabilitation and training  
*Stephane Carlier*
- 16:04 – 16:16** Thrombotic risk and antiplatelet therapy: Personalized antithrombotic strategies  
→ evolving approaches to balance thrombotic and bleeding risks.  
*Fizzah Choudry*
- 16:16 – 16:25** Discussion
- 16:25 – 16:40** Coffee break

# 2025.10.11 Saturday ROOM A

- 16:40 – 17:50 **Session 6.**  
**Advanced coronary disease: Managing complex atherosclerosis in cooperation with New Frontiers of Interventional Cardiology**  
CHAIR  
*Dariusz Dudek, Michał Hawranek, Marta Kałużna-Oleksy, Jacek Legutko*
- 16:41 – 16:53 Multivessel disease: Is revascularization always the answer?  
→ decision-making in diffuse CAD considering anatomy and comorbidities.  
*Emanuele Barbato*
- 16:53 – 17:05 Calcium everywhere: How to treat heavily calcified coronary arteries  
→ imaging, atherectomy, and lithotripsy in severe calcification.  
*Shrilla Banerjee*
- 17:05 – 17:17 Revascularization in left main and bifurcations: Anatomy meets strategy  
→ current evidence and controversies.  
*Jacek Legutko*
- 17:17 – 17:29 Chronic total occlusions: When and why should we still intervene?  
→ indications, techniques, and predictors of success.  
*Maciej Marciniak*
- 17:29 – 17:41 Heart Team strategy in advanced CAD — the role of cardiac surgery  
→ procedural planning and follow-up using the Heart Team model.
- 17:41 – 17:50 Discussion
- 17:50 – 18:05 Coffee break



18:05 – 19:15 **Session 7.**

## **Bleeding, vulnerability and complexity: How to treat the unstable patient**

**CHAIR**

*Valeria Paradies, Alicja Sottowska*

**PANEL**

*Aaysha Cader, Maciej Marciniak*

- 18:06 – 18:18** Treating patients with high bleeding risk: How low can we go?  
→ monotherapy, DAPT minimization, and individualized strategies.
- 18:18 – 18:30** PCI in complex CCS patients: Frailty, CKD, and anemia  
→ decisions in stable but high-risk patients.  
*Jacek Legutko*
- 18:30 – 18:42** Managing anticoagulation in PCI: AF, VTE, and triple therapy dilemmas  
→ strategies for managing doacs, vkas and procedural risks.  
*Bartosz Hudzik*
- 18:42 – 18:54** The Different Faces of Pulmonary Hypertension  
*Aleksander Araszkievicz*
- 18:54 – 19:06** Post-PCI algorithm - Heart Team for the complex patient  
→ integrating geriatrics, nephrology, internal medicine in interventional care.
- 19:06 – 19:15** Discussion

# 2025.10.11 Saturday ROOM B

## 12:30 – 14:00 Maximising Success in Publishing Research Papers

CHAIR:

*Professor Mark Hayter*

Professor Hayter will share his decades of experience as an editor, Editor-in-Chief, author and reviewer to discuss how to maximise success in academic writing and publishing research. This presentation will cover the '7 golden rules of writing' and the '10 top reasons for manuscript rejection' to explore how we can develop our academic writing and improve the chances of success. It will also explore the way journals and editors work, how they process reviews and the influence of citations and impact factor in their assessment of new manuscripts.



- 9:00 – 10:10 **Session 8.**  
**Destabilized: Hemodynamic collapse and the role of circulatory support**  
CHAIR  
*Marta Kałużna-Oleksy, Emanuele Barbato*  
PANEL  
*Robert J. Gil, Jerzy Sacha, Wiktor Kuliczkowski*
- 9:01 – 9:13 The final stage of vulnerability: Identifying the failing cardiovascular system  
→ clinical, hemodynamic, and biomarker indicators.  
*Giulia Masiero*
- 9:13 – 9:25 Preventing collapse in high-risk PCI: When to plan for MCS  
→ elective support strategies in borderline patients.  
*Marta Kałużna-Oleksy*
- 9:25 – 9:37 Beyond the heart: How MCS protects the brain, kidneys, and systemic function  
→ organ protection and systemic stabilization.  
*Wiktor Kuliczkowski*
- 9:37 – 9:49 National Program for the Treatment of Cardiogenic Shock — How to Implement It Effectively  
*Robert J. Gil*
- 9:49 – 10:01 The role of MCS in acute pulmonary embolism  
*Marcin Kurzyna*
- 10:01 – 10:10 Discussion
- 10:10 – 10:25 Coffee break

10:25 – 10:55 **Session 9.**  
**ESC guidelines in practice: Heart Team in action -  
Real cases with guidelines approach**  
**Part 1. Multivessel disease in a diabetic patient:  
Strategy beyond revascularization – what do the  
ESC guidelines say?**

CHAIR

*Piotr Buszman, Stephane Manzo-Silberman*

10:25 – 10:32 Case presentation: Multivessel disease in a diabetic patient -  
Strategy beyond revascularization  
*Aaysha Cader*

10:32 – 10:42 Revascularization in diabetes  
*Sarita Rao*

10:42 – 10:52 Prevention of atherosclerosis progression and late stent failure  
*Ulvi Mirzoyev*

10:52 – 10:55 Discussion

10:55 – 11:25 **Session 9.**  
**ESC guidelines in practice: Heart Team in action -  
Real cases with guidelines approach**  
**Part 2. Bleeding risk vs ischemic benefit: PCI in an  
octogenarian with AF and CKD – what do the ESC  
guidelines say?**

CHAIR

*Bartosz Hudzik, Valeria Paradies*

10:55 – 11:02 Case presentation: Bleeding risk vs ischemic benefit - PCI  
in an octogenarian with AF and CKD  
*Nicola Ryan*

11:02 – 11:12 Strategy of revascularization in high bleeding risk patients  
*Mila Kovacevic*

11:12 – 11:22 Short and long term management of patient after intervention  
*Ivan Ilic*

11:22 – 11:25 Discussion

- 11:25 – 11:55 **Session 9.**  
**ESC guidelines in practice: Heart Team in action – Real cases with guidelines approach**  
**Part 3. Young patient with multimorbidity – multilevel atherosclerosis, arrhythmia, and valvular heart disease – what do the ESC guidelines say?**  
*CHAIR: Jamal Rana, Mila Kovacevic*
- 11:25 – 11:32 Case presentation: Young patient with multimorbidity – multilevel atherosclerosis, arrhythmia, and valvular heart disease  
*Magdalena Dudek*
- 11:32 – 11:42 Multilevel atherosclerosis  
*Carmen Moldovan*
- 11:42 – 11:52 Heart rhythm disorders  
*Piotr Buchta*
- 11:52 – 11:55 Discussion
- 11:55 – 12:10 Coffee break
- 12:10 – 13:20 **Session 10.**  
**Decoding HFpEF: From diagnosis to multidisciplinary care and the patient voice**  
*CHAIR: Agata Bielecka-Dąbrowa, Ercole Vellone*  
*PANEL: Izabella Uchmanowicz, Michał Hawranek, Marta Kałużna-Oleksy, Christopher Lee*
- 12:10 – 12:22 A two-phase approach to diagnosing HFpEF: Clinical scores and decision trees (lecture under the patronage of Eli Lilly)  
*Izabella Uchmanowicz*
- 12:22 – 12:34 The role of heart failure nurses in diagnosing and managing HFpEF  
*Ercole Vellone*
- 12:34 – 12:46 The multidisciplinary HF Team: Making complex care work for HFpEF  
*Massimo Piepoli*
- 12:46 – 12:58 Living with HFpEF: What patients need and what they tell us  
*Ekaterini Lambrinou*
- 12:58 – 13:20 Discussion
- 13:20 – 13:35 Coffee break

# 2025.10.12 Sunday ROOM A

13:35 – 14:45 **Session 11.**

## **Obesity in women**

**CHAIR**

*Pierre Sabouret, Miłosz Jaguszewski*

**PANEL**

*Izabella Uchmanowicz, Marta Kałużna-Oleksy, Michał Hawranek*

- 13:35 – 13:47 Obesity and inflammation as drivers of ASCVD: Sex-specific risks and mechanisms  
*Marta Kałużna-Oleksy*
- 13:47 – 13:59 Optimising Medical Therapy and Interventions for Patients with Obesity in the Acute Cardiac Care Unit  
*Antonia Sambola*
- 13:59 – 14:11 Female-specific cardiometabolic pathways: PCOS, menopause, and the inflammatory cascade  
*Stephane Manzo-Silberman*
- 14:11 – 14:23 Lifestyle and hormonal modulation of cardiovascular risk in obese women  
*Biljana Parapid*
- 14:23 – 14:35 Beyond conventional risk factors: Priorities in women's cardiovascular health  
*Valeria Paradies*
- 14:35 – 14:45 Discussion
- 14:45 – 15:00 Coffee break



# 2025.10.12 Sunday ROOM A

15:00 – 16:10 **Session 12.**

## **The Prevention&Intervention Heart Team model: Putting it all together**

CHAIR

*Izabella Uchmanowicz, Marta Kałużna-Oleksy, Michał Hawranek*

- 15:00 – 15:12 What we learned about risk and instability in ASCVD  
→ summary of biological, anatomical, and clinical risk markers.  
*Jamal Rana*
- 15:12 – 15:24 The expanding role of interventional cardiology in team-based  
ASCVD care  
→ from proceduralist to strategic leader.  
*Michał Hawranek*
- 15:24 – 15:36 How to organize a real Heart Team  
→ team structure, roles, and collaboration points.  
*Izabella Uchmanowicz*
- 15:36 – 15:48 What's next? The future of prevention and intervention  
→ AI, data integration, teleconsultations, and population-level  
engagement.  
*Christopher Lee*
- 15:48 – 16:10 Discussion
- 13:00 – 15:00 Lunch time

# 2025.10.12 Sunday FOYER

## 10:00 – 12:00 ABSTRACT SESSION

### CHAIR:

*Michał Czapla, Grzegorz Kubiela, Jakub Morze, Bartosz Uchmanowicz, Izabella Uchmanowicz*

1. Intracoronary adrenaline for the treatment of refractory no-reflow phenomenon during percutaneous coronary intervention: Insights from the MIRACLE-NR registry – *Piotr Desperak*
2. Lp(a) levels in patients with a confirmed diagnosis of heterozygous Familial Hypercholesterolemia – *Julia Warzywoda*
3. Mediterranean Diet Adherence and Body Composition in Post-Myocardial Infarction Patients: Preliminary Findings from the CARE-ME Study – *Michał Mazur*
4. The relationship between gestational diabetes mellitus and the incidence of cardiovascular disease during the extended postnatal period – *Marta Ryś*
5. Functional capacity and exercise tolerance in nursing home residents with treated arterial hypertension and coronary heart disease – *Małgorzata Fortuna*
6. Impact of the Polish National Preventive Program “prophylaxis 40 plus” on cardiovascular polypharmacy reduction and therapeutic optimization in multimorbid middle-aged adults – *Jacek Gonos*
7. Association between Frailty and Functional Independence in Older Patients with Heart Failure – *Jagoda Janiszewska*
8. Ethnic differences in aortic and femoral artery measurements in TAVI patients – DIVER registry – *Anna Olasińska-Wiśniewska*
9. Prevalence of depression symptoms and social anxiety in hospitalized heart failure patients – cross-sectional study – *Nela Wiśniewska*
10. ChatGPT in cardiovascular medicine: revolution, hype, or helper? – Sara Janczak
11. Treatment of heart failure in the Polish population based on the EVOLUTION-HF study – is there therapeutic inertia? – *Przemysław Leszek*
12. Coverage of psychological care and burden of mental health disorders in HF patients – *Filip Sawczak*
13. Relaxation methods as an effective non-pharmacological intervention to reduce blood pressure during pregnancy and the postpartum period – *Kamila Drobina*
14. Effective psychotherapeutic intervention in a patient with Barlow syndrome, hypertension and panic attacks after ascending aorta surgery – *Anna Prokopowicz*
15. Assessment of patient satisfaction with participation in a vascular disease prevention program at sp zoz kamieński – *Ewa Molka*
16. Evaluation of the effectiveness of the cardiovascular disease prevention program in Kobbelt Wielkie, Łódź voivodeship – *Ewa Molka*



## 10:25 – 11:55 WORKSHOP

### Case challenge with Shockwave IVL

#### CHAIR:

*Marta Kałużna-Oleksy, Michał Hawranek*

Shockwave IVL: Expanding horizons in the treatment of coronary calcification (15 min.) – *Michał Hawranek*

Case 1 (10 min.) – *Anna Mosiądz*

Case 2 (10 min.) – *Łukasz Pyka*

Case 3 (10 min.) – *Anastasiya Skoromna*

Case 4 (10 min.) – *Michał Wróbel*

Case 5 (10 min.) – *Anna Draus*

IVL in registries (15 min.) – *Wojciech Skorupski*

How to deal with Shockwave-IVL in everyday practice

– session summary (10 min.) – *Marta Kałużna-Oleksy*